“DEB has the power to redefine how (bio)chemical materials will look in the 21st century: tailored, functional, nature-inspired and safer,” said Leticia Gonçalves, president of Health & Biosciences at IFF. “It brings together biotechnology, molecular design and sustainability to deliver solutions that were unimaginable just a few years ago. This launch is just the beginning — DEB’s potential reaches far beyond any single category, and we’re exploring what sustainability and performance benefits it can unlock across different industries.”

Developed by IFF’s Health & Biosciences business unit, the DEB platform leverages advanced bioscience to create unique and structurally diverse polysaccharides like those found in nature, but at scale, with accuracy and consistency typically only found in traditional industrial polymers. Engineered from renewable plant sugar sources, these biomaterials are customized to enable tailored functionality and deliver specific performance attributes across applications. In laundry formulations, the Lyrature™ portfolio with DEB-based products will replace persistent, non-biodegradable ingredients such as polyquaterniums, offering a bio-based solution that enhances surface modification and supports anti-redeposition benefits.

IFF is further scaling DEB through its joint venture with Kemira, Alpha Bio, which will house a first-of-its-kind manufacturing asset dedicated to DEB-based materials. Following extensive process and product validation at the Kokemäki and Jokioinen plants in Finland, AlphaBio is working with a growing network of customers and partners to bring DEB-based solutions from this facility to multiple market sectors starting in 2027. As the platform evolves, IFF is focused on unlocking its full potential, delivering products that meet the demands of modern performance while advancing a more sustainable future across industries, including health, nutrition, beauty, packaging, and more.

To learn more about the DEB platform, visit: IFF | Designed Enzymatic Biomaterials™ (DEB)

Cautionary Statement under the Private Securities Litigation Reform Act of 1995

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “plan”, “expect,” “anticipate,” “intend,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the timing or nature of future product launches, and commercial partnerships. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances.